StockData
Iovance Biotherapeutics, Inc. logo

Iovance Biotherapeutics, Inc. (IOVA) stock

IOVANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3087% above fair value
$7.53−0.02 (-0.26%)

Close on Nov 17, 2026Market cap $3.41BP/E –Yield –

Iovance Biotherapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Iovance Biotherapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$276.26M. For fiscal 2025 it was -$390.49M. The highest annual figure on record is -$14.44K in fiscal 2009.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$390.49M–
FY2024Dec 31, 2024-$384.02M–
FY2023Dec 31, 2023-$448.99M–
FY2022Dec 31, 2022-$389.57M–
FY2021Dec 31, 2021-$339.59M–
FY2020Dec 31, 2020-$260.80M–
FY2019Dec 31, 2019-$205.70M–
FY2018Dec 31, 2018-$127.30M–
FY2017Dec 31, 2017-$91.93M–
FY2016Dec 31, 2016-$52.66M–
FY2015Dec 31, 2015-$26.86M–
FY2014Dec 31, 2014-$11.95M–
FY2013Dec 31, 2013-$22.63M–
FY2012Dec 31, 2012-$8.13M–
FY2011Dec 31, 2011-$21.22M–
FY2010Dec 31, 2010-$756.82K–
FY2009Dec 31, 2009-$14.44K–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$42.41M–
Q1 FY2026Mar 31, 2026-$78.22M–
Q4 FY2025Dec 31, 2025-$69.74M–
Q3 FY2025Sep 30, 2025-$85.89M–
Q2 FY2025Jun 30, 2025-$104.42M–
Q1 FY2025Mar 31, 2025-$118.65M–
Q4 FY2024Dec 31, 2024-$83.30M–
Q3 FY2024Sep 30, 2024-$79.34M–
Q2 FY2024Jun 30, 2024-$98.91M–
Q1 FY2024Mar 31, 2024-$114.74M–
Q4 FY2023Dec 31, 2023-$118.31M–
Q3 FY2023Sep 30, 2023-$115.46M–
Q2 FY2023Jun 30, 2023-$107.19M–
Q1 FY2023Mar 31, 2023-$108.09M–
Q4 FY2022Dec 31, 2022-$104.22M–
Q3 FY2022Sep 30, 2022-$97.90M–
Q2 FY2022Jun 30, 2022-$97.53M–
Q1 FY2022Mar 31, 2022-$89.92M–
Q4 FY2021Dec 31, 2021-$98.12M–
Q3 FY2021Sep 30, 2021-$85.21M–
Q2 FY2021Jun 30, 2021-$81.06M–
Q1 FY2021Mar 31, 2021-$75.20M–
Q4 FY2020Dec 31, 2020-$68.21M–
Q3 FY2020Sep 30, 2020-$58.66M–
Q2 FY2020Jun 30, 2020-$63.37M–
Q1 FY2020Mar 31, 2020-$70.56M–
Q4 FY2019Dec 31, 2019-$64.82M–
Q3 FY2019Sep 30, 2019-$51.30M–
Q2 FY2019Jun 30, 2019-$49.88M–
Q1 FY2019Mar 31, 2019-$39.72M–
Q4 FY2018Dec 31, 2018-$34.69M–
Q3 FY2018Sep 30, 2018-$34.81M–
Q2 FY2018Jun 30, 2018-$31.15M–
Q1 FY2018Mar 31, 2018-$26.65M–
Q4 FY2017Dec 31, 2017-$25.83M–
Q3 FY2017Sep 30, 2017-$22.10M–
Q2 FY2017Jun 30, 2017-$23.34M–
Q1 FY2017Mar 31, 2017-$20.66M–
Q4 FY2016Dec 31, 2016-$15.63M–
Q3 FY2016Sep 30, 2016-$18.83M–

More Iovance Biotherapeutics figures

See a number that looks wrong?